Joseph Dowling

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2

Hemp-Focused CV Sciences Reports Steady Q1 Revenue Amid Operational Hurdles And Acquisition Of Nutraceuticals Manufacturer

Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2

Hemp-Focused CV Sciences Reports Steady Q1 Revenue Amid Operational Hurdles And Acquisition Of Nutraceuticals Manufacturer

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

Capitalizing On Plant-Based Trend: Cultured Foods Acquisition Allows This US Hemp Co. To Expand In Europe

Hemp-Focused Wellness Co. Moves Closer To Profitability, Reports Flat 2023 Revenue, Increase In Gross Profit

Capitalizing On Plant-Based Trend: Cultured Foods Acquisition Allows This US Hemp Co. To Expand In Europe

Hemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%

Publicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To Know

Joseph Dowling Recent News

CV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To Know

CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4 million for the first quarter of 2022 and a sequential increase of 7%.

CV Sciences FY22 Revenue Declines 19% To $16.2M

CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights

CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next

CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697.

Why Is CV Sciences Stock Up Today?

CV Sciences (OTCQB: CVSI) shares were trading 10.69% higher at $0.044 per share at the time of writing Monday morning on company's third-quarter financial results.

EXCLUSIVE: Keep Calm And Carry CBD Softgels With THC, CV Sciences Launches Relaxation Products

Hemp CBD manufacturer CV Sciences, Inc. (OTCQB: CVSI) has launched +PlusCBD Reserve Collection softgels to support stress relief and relaxation. This new CBD collection will be available online starting August 15th at $54.99 per 60-count bottle.

CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share

CV Sciences, Inc. (OTCQB: CVSI) released its financial results for the quarter ended March 31, 2022, revealing a revenue drop of 8.33% to $4.4 million YoY. First Quarter 2022 and Recent Financial and Operating Highlights

CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products

CV Sciences, Inc. (OTCQB: CVSI) added +PlusCBD Relief Softgels to its wellness line of CBD products.

CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients

CV Sciences, Inc. (OTCQB: CVSI) is launching +PlusCBD Pain Relief topicals.

CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation

CV Sciences, Inc. (OTCQB: CVSI), a supplier and manufacturer of hemp cannabidiol (CBD) products, announced its financial results for the quarter on Monday, Nov 15. Third Quarter 2021 and Recent Financial and Operating Highlights: